德克拉伐替尼 (BMS-986165)

Name: 德克拉伐替尼 (BMS-986165)
Brand: 济南圣和化工有限公司

CAS 1609392-27-9C20H22N8O3MW 425.5

德克拉伐替尼 (BMS-986165)，CAS 登记号 1609392-27-9，由济南圣和化工有限公司现货供应，可提供纯度按批次COA提供(不公开发布) 的规格，下游主要用于医药原料；医药中间体及原料药。支持样品与小批量试用，批量价格请联系我们获取，验收以批次 COA 为准。

规格参数

CAS号1609392-27-9

分子式C20H22N8O3

分子量425.5

LogP1.2

纯度按批次COA提供(不公开发布)

包装按订单/批次确认(不公开发布)

应用领域医药原料；医药中间体及原料药

类别医药原料|医药中间体及原料药

用途与场景

医药原料；医药中间体及原料药

包装与供货

包装规格按订单/批次确认(不公开发布)

纯度规格按批次COA提供(不公开发布)

储存条件密封、阴凉干燥处保存

供货周期现货/按订单安排

文件与支持

每批随货提供 COA；可按需提供 MSDS 及技术文件。邮件注明产品名称与 CAS 号，一个工作日内回复报价。

常见问题

在哪里能查到德克拉伐替尼 (BMS-986165) 的 CAS 号？

本页已列出德克拉伐替尼 (BMS-986165) 的 CAS 号：1609392-27-9，可与随货 COA 核对。

可以提供哪些规格和包装？

常见纯度为按批次COA提供(不公开发布)，包装形式为按订单/批次确认(不公开发布)，特殊规格可在询价时说明。

德克拉伐替尼 (BMS-986165) 一般用在什么产品里？

主要涉及医药原料；医药中间体及原料药。

下单流程是怎样的？

来信 info@591daili.com 或 WhatsApp 联系，提供产品名称、CAS 号与数量，确认价格与交期后即可安排发货，验收以批次 COA 为准。

PubChem 公开数据

Description

Deucravacitinib (BMS-986165) · CAS 1609392-27-9 · C20H22N8O3. UNII N0A21N6RAU.

Identification

CAS Registry Number	1609392-27-9
PubChem CID	134821691
Molecular formula	C20H22N8O3
IUPAC name	6-(cyclopropanecarbonylamino)-4-[2-methoxy-3-(1-methyl-1,2,4-triazol-3-yl)anilino]-N-(trideuteriomethyl)pyridazine-3-carboxamide
UNII (FDA)	N0A21N6RAU

Computed Descriptors

Molecular Weight	425.5
XLogP3	1.2
Hydrogen Bond Donor Count	3
Hydrogen Bond Acceptor Count	8
Rotatable Bond Count	7
Exact Mass	425.20031683
Monoisotopic Mass	425.20031683
Topological Polar Surface Area	136
Heavy Atom Count	31
Formal Charge	0

Regulatory Status

GHS notification summary	33.3% (1 / 3)

GHS Hazard Classification

GHS notification summary	33.3% (1 / 3)
Reported hazard statements	H361 (33.3%), H372 (66.7%)

This chemical does not meet GHS hazard criteria for 33.3% (1 of 3) of reports.

H361 (33.3%): Suspected of damaging fertility or the unborn child [Warning Reproductive toxicity]

Documented Uses

Deucravacitinib is a tyrosine kinase 2 (TYK2) inhibitor indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. It is not recommended for use in combination with other potent immunosuppressants. It is also indicated for the treatment of psoriatic arthritis in adults.
Deucravacitinib is a small molecule inhibitor of tyrosine kinase 2 that is used in the treatment of moderate-to-severe plaque psoriasis. Deucravacitinib is associated with transient and usually mild elevations in serum aminotransferase levels during therapy but has not been linked instances of clinically apparent acute liver injury.
Breast Feeding; Lactation; Milk, Human; Dermatologic Agents; Enzyme Inhibitors; Protein Kinase Inhibitors; Tyrosine Kinase Inhibitors; Signal Transduction Inhibitors; Janus Kinase Inhibitors; JAK Inhibitors
Take with or without food. Food has no clinically significant effect on drug absorption and exposure.
Drugs used to treat or prevent skin disorders or for the routine care of skin.
Protein kinase inhibitors that inhibit TYROSINE PROTEIN KINASES.

Synonyms

Deucravacitinib; 1609392-27-9; BMS-986165; Sotyktu; N0A21N6RAU; RefChem:58358; Tyk2-IN-4; BMS986165; Deucravacitinib [USAN]; MFCD31715455; Deucravacitinib (BMS-986165); Tyk2-IN-4(BMS986165); bms 986165; Sotyktu (TN); Deucravacitinib [MI]; UNII-N0A21N6RAU

Frequently Asked Questions

What are the CAS number and molecular formula of Deucravacitinib (BMS-986165)?

CAS 1609392-27-9; molecular formula C20H22N8O3; molecular weight — g/mol.

What other names is Deucravacitinib (BMS-986165) known by?

Deucravacitinib, 1609392-27-9, BMS-986165, Sotyktu, N0A21N6RAU, RefChem:58358.

Is Deucravacitinib (BMS-986165) classified as hazardous?

33.3% of GHS notifications report no hazard classification (1 of 3).

Facts on this page are taken from PubChem (US National Library of Medicine) and Wikidata. Grade-specific data — assay, moisture, particle size, packaging, shelf life — is issued per batch on the COA and is not published here.

获取德克拉伐替尼 (BMS-986165) 报价

供应商：济南圣和化工有限公司 · 一个工作日内回复。

邮件询价 WhatsApp